milrinone has been researched along with Cardiovascular Diseases in 6 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction hospitalized for worsening heart failure to receive 48 to 72 hours of intravenous milrinone or placebo in addition to standard therapy." | 9.11 | Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s ( Adams, KF; Califf, RM; Felker, GM; Gattis-Stough, W; Gheorghiade, M; Klein, L; Leimberger, JD; O'Connor, CM; Piña, IL, 2005) |
| "Milrinone (MRN) is a widely known cardiac inotrope drug used for the treatment of congestive heart failure in patients, however, its efficacy is limited." | 5.48 | Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and in Vitro Characterization. ( Gaudreault, F; Lomis, N; Malhotra, M; Prakash, S; Shum-Tim, D; Westfall, S, 2018) |
| "We analyzed data from the OPTIME-CHF (Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure) study, a randomized trial of intravenous milrinone versus placebo in 949 patients hospitalized with ADHF." | 5.12 | Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. ( Califf, RM; Cuffe, MS; Echols, MR; Felker, GM; Garg, J; Gheorghiade, M; O'Connor, CM; Pieper, KS; Thomas, KL, 2006) |
| "The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction hospitalized for worsening heart failure to receive 48 to 72 hours of intravenous milrinone or placebo in addition to standard therapy." | 5.11 | Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s ( Adams, KF; Califf, RM; Felker, GM; Gattis-Stough, W; Gheorghiade, M; Klein, L; Leimberger, JD; O'Connor, CM; Piña, IL, 2005) |
| "This milrinone regimen was evaluated in stage two (n = 10)." | 1.34 | Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. ( Evans, N; Jiang, X; Kluckow, M; McLachlan, AJ; Osborn, D; Paradisis, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lomis, N | 1 |
| Gaudreault, F | 1 |
| Malhotra, M | 1 |
| Westfall, S | 1 |
| Shum-Tim, D | 1 |
| Prakash, S | 1 |
| Mischnik, M | 1 |
| Boyanova, D | 1 |
| Hubertus, K | 1 |
| Geiger, J | 1 |
| Philippi, N | 1 |
| Dittrich, M | 1 |
| Wangorsch, G | 1 |
| Timmer, J | 1 |
| Dandekar, T | 1 |
| Gabr, RQ | 1 |
| Elsherbiny, ME | 1 |
| Somayaji, V | 1 |
| Pollak, PT | 1 |
| Brocks, DR | 1 |
| Klein, L | 1 |
| O'Connor, CM | 2 |
| Leimberger, JD | 1 |
| Gattis-Stough, W | 1 |
| Piña, IL | 1 |
| Felker, GM | 2 |
| Adams, KF | 1 |
| Califf, RM | 2 |
| Gheorghiade, M | 2 |
| Paradisis, M | 1 |
| Jiang, X | 1 |
| McLachlan, AJ | 1 |
| Evans, N | 1 |
| Kluckow, M | 1 |
| Osborn, D | 1 |
| Echols, MR | 1 |
| Thomas, KL | 1 |
| Pieper, KS | 1 |
| Garg, J | 1 |
| Cuffe, MS | 1 |
2 trials available for milrinone and Cardiovascular Diseases
| Article | Year |
|---|---|
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Female; Heart Failure; Hosp | 2005 |
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.
Topics: Acute Disease; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Car | 2006 |
4 other studies available for milrinone and Cardiovascular Diseases
| Article | Year |
|---|---|
Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and in Vitro Characterization.
Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Cell Line; Circular Dichroism; Drug Carriers; | 2018 |
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integr | 2013 |
A liquid chromatography-mass spectrometry method for nicotine and cotinine; utility in screening tobacco exposure in patients taking amiodarone.
Topics: Amiodarone; Cardiovascular Diseases; Chromatography, Reverse-Phase; Cotinine; Humans; Liquid-Liquid | 2011 |
Population pharmacokinetics and dosing regimen design of milrinone in preterm infants.
Topics: Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Infant, Prematur | 2007 |